NCT06345404

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic Dermatitis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: Corvus Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD

Detailed description

A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants with Moderate to Severe Atopic Dermatitis

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Soquelitinib	Tablets
DRUG	Placebo	Soquelitinib matching placebo tablets

Timeline

• Start date: 2024-04-16
• Primary completion: 2026-01-28
• Completion: 2026-02-24
• First posted: 2024-04-03
• Last updated: 2026-03-12

Locations

16 sites across 1 country: United States

Regulatory

• FDA-regulated drug study